Description

DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is about 3-10-fold more potent than the parent agent Maytansine, with IC50s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines[1].-4°C (Powder, protect from light)-Applications-Cancer-programmed cell death-Formula-C36H50ClN3O10S2-Citation–References-[1]Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(11):1860-1867. |[2]Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107. -CASNumber-138148-68-2-MolecularWeight-784.38-Compound Purity-98.02-SMILES-C[C@]12[C@@]([C@@H]([C@]3([H])C[C@]([C@@H](/C=C/C=C(CC4=CC(N(C(C[C@@H]2OC([C@H](C)N(C)C(CCSSC)=O)=O)=O)C)=C(C(OC)=C4)Cl)C)OC)(NC(O3)=O)O)C)([H])O1-Research_Area-Cancer-Solubility-DMSO : 100 mg/mL (ultrasonic)-Target-ADC Cytotoxin;Microtubule/Tubulin-Isoform-Maytansinoids-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related